Trial reportClinical journal of the American Society of Nephrology : CJASN2012
Correction of metabolic acidosis with potassium citrate in renal transplant patients and its effect on bone quality.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Normal saline versus lower-chloride solutions for kidney transplantation.The Cochrane database of systematic reviews · 2016Pooled it
- Correction of chronic metabolic acidosis for chronic kidney disease patients.The Cochrane database of systematic reviews · 2007Pooled it
- Metallomic characterization of induced periapical lesions-In vivo study.International endodontic journal · 2025Article
- Potassium/Sodium Citrate Attenuates Paclitaxel-Induced Peripheral Neuropathy.International journal of molecular sciences · 2025Article
- [What is confirmed in the treatment of metabolic acidosis in chronic kidney disease?]Innere Medizin (Heidelberg, Germany) · 2024Review
- The relationship between anti-seizures medications and metabolic acidosis in craniotomy operations: is topiramate or zonisamide the cause of metabolic acidosis?BMC anesthesiology · 2024Article
- Metabolic Acidosis in CKD: Pathogenesis, Adverse Effects, and Treatment Effects.International journal of molecular sciences · 2024Review
- A specialized metabolic pathway partitions citrate in hydroxyapatite to impact mineralization of bones and teeth.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Preclinical and Clinical Evidence of Effect of Acid on Bone Health.Advances in chronic kidney disease · 2022Review
- Effects of acid on bone.Kidney international · 2022Review
- Article
- Early pH Changes in Musculoskeletal Tissues upon Injury-Aerobic Catabolic Pathway Activity Linked to Inter-Individual Differences in Local pH.International journal of molecular sciences · 2020Article
- Interventions for preventing bone disease in kidney transplant recipients.The Cochrane database of systematic reviews · 2019Review
- Metabolic Acidosis and Subclinical Metabolic Acidosis in CKD.Journal of the American Society of Nephrology : JASN · 2018Review
- Acidosis and Kidney Allograft Survival.Journal of the American Society of Nephrology : JASN · 2017Article
- Metabolic Acidosis and Long-Term Clinical Outcomes in Kidney Transplant Recipients.Journal of the American Society of Nephrology : JASN · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcidosis and transplantation are associated with increased risk of bone disturbances. This study aimed to assess bone morphology and metabolism in acidotic patients with a renal graft, and to ameliorate bone characteristics by restoration of acid/base homeostasis with potassium citrate.
methodsThis was a 12-month controlled, randomized, interventional trial that included 30 renal transplant patients with metabolic acidosis (S-[HCO(3)(-)] <24 mmol/L) undergoing treatment with either potassium citrate to maintain S-[HCO(3)(-)] >24 mmol/L, or potassium chloride (control group). Iliac crest bone biopsies and dual-energy X-ray absorptiometry were performed at baseline and after 12 months of treatment. Bone biopsies were analyzed by in vitro micro-computed tomography and histomorphometry, including tetracycline double labeling. Serum biomarkers of bone turnover were measured at baseline and study end. Twenty-three healthy participants with normal kidney function comprised the reference group.
resultsAdministration of potassium citrate resulted in persisting normalization of S-[HCO(3)(-)] versus potassium chloride. At 12 months, bone surface, connectivity density, cortical thickness, and cortical porosity were better preserved with potassium citrate than with potassium chloride, respectively. Serological biomarkers and bone tetracycline labeling indicate higher bone turnover with potassium citrate versus potassium chloride. In contrast, no relevant changes in bone mineral density were detected by dual-energy X-ray absorptiometry.
conclusionsTreatment with potassium citrate in renal transplant patients is efficient and well tolerated for correction of metabolic acidosis and may be associated with improvement in bone quality. This study is limited by the heterogeneity of the investigated population with regard to age, sex, and transplant vintage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.